about
Extrahepatic manifestations of chronic hepatitis C virus infectionSystemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literaturePulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literatureComparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levelsAnti-C1q antibodies in hepatitis C virus infectionRapid and early virological response to chronic hepatitis C treatment with IFN 2b or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patientsOccult Hepatitis C Virus Infection Revisited with Ultrasensitive Real-Time PCR AssayPatient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational studyHepatitis C Therapy in Renal Patients: Who, How, When?Hyperhomocysteinemia and arterial aneurysmClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsPatients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialCardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature reviewPegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trialErdheim-Chester disease. Clinical and radiologic characteristics of 59 casesCNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patientsPanic attack after therapeutic administration of mefloquineHepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemiaPolymyositis induced by tiopronineKaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's diseaseInternational and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.[Vitamin D and autoimmunity. First part: Fundamental aspects].Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry.Systemic vasculitis in patients with hepatitis C.Meta-analyses of FibroTest diagnostic value in chronic liver disease.Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C.[A non-automatic diagnosis].Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome.Hepatitis C virus-associated extrahepatic manifestations: a review.[Catastrophic antiphospholipid syndrome].Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24Behçet's disease and pregnancy.Autoimmune diseases in HIV-infected patients: 52 cases and literature review.Tocilizumab in severe and refractory non-infectious uveitis.Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.Anticardiolipin, anti-beta2-glycoprotein I, and antinucleosome antibodies in hepatitis C virus infection and mixed cryoglobulinemia. Multivirc Group.Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study.Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
P50
Q26767084-041CA808-B0C0-4086-BE67-23F9A1E82717Q27004258-728D6D5A-5099-4F57-9E73-987583A9C9F8Q27008053-A1E133C7-4567-4FF5-AB59-A95F2C82F77CQ27473034-9A24E551-8F25-45A5-AC66-2A894CAFDE11Q27477959-9566192F-E5CC-464B-8FCC-DD5AD0532130Q27478132-54309330-DB3C-479B-ACE4-C95FA31146C7Q27481046-E27E03B9-0CC9-4795-BDB8-FB76A011C2A4Q27486401-C5FB7524-33A7-4100-9227-C6C8D1D4231CQ27490163-EA5DEA1C-DA39-4F34-B9C4-610E738474EEQ28077130-B2F78C6C-5358-4C26-99F1-D222A3BD88FFQ28192583-38B590D1-93C9-49AE-819C-ABE72558C728Q28195656-54A34DB6-5292-4E44-BE61-6F99925178EDQ28210537-41BE3C82-689D-4629-B00D-2DA3CC65BA8AQ28291620-B16C2BD8-024E-46F5-BA64-35A9D5E6E79FQ28298301-75880D85-43F6-443E-8B66-615BAA2F161BQ28299567-57BA01AD-C38C-400D-AC04-A7D5690D367BQ28303400-2899E4E1-5F60-464E-8087-FA7EB10B259AQ28325759-968F392C-09C0-421D-9BEF-6F95F1C3DDFEQ28348490-A60C8FAA-6CF8-4B96-B4DF-910954202EB0Q28377493-5C24AE04-29BD-4820-97AD-3418B0F809EDQ29619158-ABD72ADF-B7A0-4719-B880-49110251069BQ30234696-CD3FBE42-EE55-48A4-BA35-799942C5A2A3Q30411161-41EBFDAD-A1B2-4905-A754-969278CBB56DQ31012265-235E13B5-87D4-4397-B05F-8BEC97A887B9Q31163633-D9B5A7BE-4D52-4F7D-9E29-BE6C1EE0CB9CQ31984528-5F2FC573-52B2-480B-A920-4979B69B739FQ33302708-4E763C42-2AF4-4DB6-9B8A-07B29F039B49Q33331448-C4A610CC-C2AE-41E6-8923-8C413B1613C6Q33343142-6F336412-F333-4332-AA9C-7CCF32FF028BQ33363176-ABF44B0C-06CA-4E34-A9F0-774F6C4F2E0EQ33363781-AD6BFB14-0413-4085-B3F2-5A3828E0C372Q33399770-714D557C-CB34-4169-B500-980D38BDF425Q33407192-3E27C1A2-80DC-4659-986D-FD3CC83722C5Q33408479-ECC4F0FB-CA6A-46AF-8842-69A6BA20D997Q33414717-76968889-22C1-4622-9DE1-F806112D54C9Q33417913-488F7174-54E3-49B3-ADAD-ED146DA17683Q33422958-73BBEA13-9BD7-4446-A6EF-F5DC22C5B96EQ33500894-D1186D50-EFF5-4681-A89D-662579A07A98Q33507208-C6D1D77D-8235-4B60-98CA-738933841B47Q33552965-61F82228-E918-45CD-8803-8701D6A9141C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Patrice Cacoub
@ast
Patrice Cacoub
@en
Patrice Cacoub
@es
Patrice Cacoub
@nl
Patrice Cacoub
@sl
type
label
Patrice Cacoub
@ast
Patrice Cacoub
@en
Patrice Cacoub
@es
Patrice Cacoub
@nl
Patrice Cacoub
@sl
prefLabel
Patrice Cacoub
@ast
Patrice Cacoub
@en
Patrice Cacoub
@es
Patrice Cacoub
@nl
Patrice Cacoub
@sl
P214
P106
P21
P213
0000 0000 0784 7440
P214
P31
P496
0000-0002-6727-4992
P569
2000-01-01T00:00:00Z
P735
P7859
lccn-n2009181782